rais po
ytd stock trade ev/ sale current revenu
guidanc revenu guidanc like end conserv
view dxcm actual revenu end higher initi guid
next-gen libr could potenti come summer view depend
system featur could near-term volatil stock given
momentum continu glucos monitor cgm market dxcm product
pipelin new market opportun remain bullish long-term continu
dilig potenti payer prefer lower cost system far
impact result price point move pharmaci channel
like mean price major obstacl growth view new patient
adopt cgm rapid rate mention call
doubl manufactur capac roughli year away
could highli competit product also move much larger market
rais po assum multipl ev/
revenu prior po ev/ revenu also expect revenu
estim rise materi cours maintain buy rate
new disclosur call dxcm revenu came slightli
ahead januari pre-announce report growth versu
pre-announc reiter full year guidanc
growth see first time tonight quick progress
make margin gener revenu last quarter
spent sg oper margin move
fda approv next gen transmitt last week roll
later year transmitt impact patient sinc
manufactur use flash weld instead mold less half cost
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
dexcom inc oper medic devic
compani focus design develop
continu glucos monitor cgm system
peopl diabet compani
develop small implant devic
continu measur glucos level
subcutan tissu skin real-tim
data process display patient
also alert level high low
product market physician
endocrinologist diabet educ
see sever avenu beat street
estim launch medicar
conserv assumpt util price
competit could drive upsid near term
long-term penetr non-intens type
increas total avail market opportun
also believ cgm remain top-tier
growth market patient adopt cgm
beneficiari tailwind
valu ev/sal given compani trade revenu growth
price object base revenu estim multipl line
small mid-cap med-tech compani similar revenu growth rate
market opportun
upsid risk strateg activ patient expect less impact
expect competit faster approv pipelin product
downsid risk price pressur fewer patient added/high attrit current
patient due competitor threat lack patient want adopt cgm delay
pipelin product
travi steed herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
